Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 211 results found. Search for [ National Institute of Virology ]

Results 1 to 21 of 211
PTI
April 9, 2021
A growing number of countries have either halted or limited the use of the AstraZeneca coronavirus vaccine recently over fears that it can cause serious blood clots


Rashi Bisaria
New Delhi, April 8, 2021
Global recovery underway after worst recession since WW-2: IMF head A day after the International Monetary Fund forecast a global growth of six per cent for this year, IMF Managing Director Kristalina Georgieva has said that after the worst global recession since the Second World War, the recovery is underway. The outlook, she asserted, is brighter because millions of people are benefitting from vaccinations and because of further policy support, especially in the US. SEBI fines Mukesh Am...


BusinessToday.In
April 7, 2021
Maharashtra Health Minister Rajesh Tope, while hinting at the possibility of new COVID-19 strains in the state, said, \"New strains are suspected because we are seeing other behaviours in COVID-19 patients than routine behaviours\"


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


Joe C Mathew
March 3, 2021
The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR


BusinessToday.In
March 3, 2021
Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India


BusinessToday.In
March 2, 2021
As senior citizens across the country take part in the vaccination drive, here is all the information they need two know about the two vaccines - Covaxin and Covishield


BusinessToday.In
February 19, 2021
Maharashtra reported a jump of 5,427 cases on Thursday and Mumbai reported 736 cases. Amravati has been put under a weekend lockdown and Yavatmal has been placed under restrictions


PTI
February 17, 2021
The vaccines currently approved for emergency use in India are Covishield, from the Oxford-AstraZeneca stable manufactured by Pune's Serum Institute of India, and Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology (NIV)


PB Jayakumar
New Delhi, February 5, 2021
With record healthcare expenditure and allocations focussing on mitigating the impact of Covid-19, it's a shot in the arm for the sector


PB Jayakumar
February 3, 2021
Bharat Biotech will supply initial doses to be used in the US upon Ocugen's receipt of an EUA from the US regulatory authorities


Joe C Mathew
January 27, 2021
The sera collected from Covaxin recepients (showing 99.6 percent seroconversion following vaccination) neutralised the UK variants, ICMR said


PTI
January 22, 2021
There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet


BusinessToday.In
January 19, 2021
Close on the heels of some adverse incidents being reported, a detailed fact sheet released by Bharat Biotech says those with bleeding disorders or on blood thinners should avoid taking the shot for now


BusinessToday.In
January 11, 2021
COVID-19 vaccines for 3 crore healthcare and frontline workers, which are to be administered in the beginning of the vaccination drive, will be paid by the central government


Rajeev Dubey
New Delhi, January 6, 2021
The vaccine produced by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology, Pune, has courted many controversies since it began its first human trials. In this video, Bharat Biotech chief Dr Krishna Ella talks to Business Today Editor, Rajeev Dubey, about vaccine efficacy and why people get suspicious about Indian companies.


BusinessToday.In
January 5, 2021
Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Comprehensive contact tracing has been initiated for co-travellers, family contacts and others.  Genome sequencing on other specimens is going on, says the government


BusinessToday.In
January 3, 2021
The ICMR head emphasised that the scientists at ICMR have been successfully able to culture the UK strain and the efficacy of Covaxin against it will be further tested in days to come


PAGES 1 OF 11  12345